Neurocrine Biosciences (NBIX) CEO Gano acquired 614 shares
CEO Gano Kyle vested 614 RSU shares; 332 withheld for taxes at $146.10, no shares sold; holdings now 155,010.
Insider transactions reported
Kyle Gano (Chief Executive Officer at Neurocrine Biosciences Inc., NBIX) reported that they acquired 614 shares, and gave up 332 shares at $146.10 to cover taxes or an exercise price on Nov 1, 2026. After these transactions the filing shows 155,010 shares held directly.
- Reporting person
- Gano Kyle
- Role
- Chief Executive Officer
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Nov 1, 2026 | Exercise or conversion of a derivative (M) | Common Stock | +614 | - | - | 155,342 direct |
| Nov 1, 2026 | Shares withheld for taxes or exercise price (F) | Common Stock1 | -332 | $146.10 | $48.5K | 155,010 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Nov 1, 2026 | Exercise or conversion of a derivative (M) | Restricted Stock UnitOn 614 Common Stock2, 3 | -614 | - | - | 1,228 direct |
Holdings before and after
- Common Stock: 154,728 to 155,010 direct
- Restricted Stock Unit: 1,842 to 1,228 direct
Footnotes from the filing
- 1. Shares withheld by Neurocrine Biosciences, Inc. (the Company or Issuer ) to satisfy tax withholding requirements on vesting of restricted stock units ( RSUs ). No shares were sold.
- 2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- 3. This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, vested as to 614 shares on November 1, 2026 and will vest as to 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award.
Transaction codes in this filing
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
- Shares withheld for taxes or exercise price:
- Code F marks shares handed back or withheld to pay taxes or an exercise price. No sale happens in the market.
FAQ
What did Gano report in this NBIX Form 4?
Kyle Gano (Chief Executive Officer at Neurocrine Biosciences Inc., NBIX) reported that they acquired 614 shares, and gave up 332 shares at $146.10 to cover taxes or an exercise price on Nov 1, 2026. After these transactions the filing shows 155,010 shares held directly.
How many NBIX shares does Gano hold after this filing?
The filing shows 155,010 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code M mean on an SEC Form 4?
Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
Historical context for NBIX
Across the 28 sessions after earlier NBIX headlines, the stock closed higher 14 times and lower 14 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NBIX | SPY |
|---|---|---|---|
| Nov 4, 2026 | Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress | +0.7% | +1.7% |
| Nov 3, 2026 | Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results | +13.4% | +0.3% |
| Oct 30, 2026 | Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia | -0.2% | -1.8% |
| Oct 26, 2026 | Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia | +2.2% | +0.7% |
| Oct 23, 2026 | Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome | -0.4% | -0.5% |
| Oct 20, 2026 | Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease | +3.7% | +0.3% |
Earlier insider filings at NBIX
- Sep 15, 2026Chief Scientific Officer Onyia Jude was granted 3,587 shares and covered exercise/tax liability with 1,936 shares, increasing direct ownership by 8% to 22,647 units (SEC Form 4) to satisfy withholding tax
- Sep 15, 2026Chief Legal Officer Lippoldt Darin was granted 4,483 shares and covered exercise/tax liability with 2,419 shares, increasing direct ownership by 4% to 56,793 units (SEC Form 4) (withholding obligation)
- Sep 15, 2026Chief Medical Officer Keswani Sanjay Chandru was granted 3,914 shares and covered exercise/tax liability with 2,112 shares, increasing direct ownership by 122% to 3,281 units (SEC Form 4) to satisfy tax liability
- Sep 15, 2026Director Gorman Kevin Charles was granted 14,343 shares and covered exercise/tax liability with 7,839 shares, increasing direct ownership by 1% to 517,797 units (SEC Form 4) to cover taxes
- Sep 15, 2026Chief Executive Officer Gano Kyle was granted 8,117 shares and covered exercise/tax liability with 4,380 shares, increasing direct ownership by 2% to 154,728 units (SEC Form 4) (tax withholding)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1996
Follow NBIX and get a push notification the moment its next story breaks.